Merck (MRK) Receives EMA Recommendation for Conditional Marketing Authorization of Nobivac NXT, the World's First Feline RNA Vaccine
World's First Animal RNA Vaccine Approved
The European Medicines Agency (EMA), through its Committee for Medicinal Products for Veterinary Use (CVMP), has recommended marketing authorization for Merck & Co., Inc.'s (MRK) Nobivac NXT HCPChFeLV, a combination vaccine for cats. This vaccine is the world's first animal RNA vaccine, utilizing self-amplifying RNA (saRNA) technology in its component that prevents feline leukemia virus (FeLV). Unlike conventional inactivated vaccines, this vaccine induces a strong immune response by prompting host cells to directly produce antigens. This recommendation marks a significant milestone, signaling the beginning of the full-scale commercialization of messenger RNA (mRNA) and RNA platforms in the animal pharmaceutical market.
Maximizing Safety and Efficacy Through Hybrid Technology
This vaccine employs a hybrid approach, combining saRNA technology for the feline leukemia virus (FeLV) component with live attenuated methods for the remaining four diseases. It simultaneously delivers antigens for feline herpesvirus 1 (FHV-1), calicivirus (FCV), panleukopenia virus (FPLV), and Chlamydia felis, significantly expanding the scope of prevention. After undergoing 15 controlled trials and a field trial involving 142 cats, the vaccine demonstrated excellent immunogenicity and safety. Notably, it eliminates the need for adjuvants and preservatives commonly used to induce immunogenicity, reducing the risk of pain or adverse reactions at the injection site.
A New Generation of Feline Vaccines and Merck's Strengthened Position
The global feline vaccine market is estimated at approximately $1.5 billion (USD) in 2025 and is expected to continue its steady growth, driven by the increasing number of pet-owning households. Competitors such as Zoetis (ZTS) and Boehringer Ingelheim, which have traditionally dominated the market, still rely on inactivated and live vaccines. Merck is proactively launching its Nobivac NXT line, based on saRNA technology, in the European market, securing a leading position in the next-generation animal vaccine market. The fact that a rapid protective immunity against feline leukemia can be achieved within just one week after vaccination with a low dose of 0.5mL is a key competitive advantage that is expected to reshape the market.
Securing a New Growth Engine for the Animal Biotechnology Industry
The EMA's recommendation demonstrates the successful application of RNA platform technology, which has been validated for human use, to the animal biotechnology sector. RNA vaccines offer the advantages of flexible production conversion and significantly reduced new vaccine development times compared to conventional vaccine manufacturing facilities. Thanks to these inherent advantages of the platform, Merck will be able to respond most quickly to new animal variant viruses or emerging infectious diseases in the future. As a result, this approval will not only be a launch of individual products but also a catalyst for advancing the technological paradigm of the entire preventive medicine industry for pets.
This EMA recommendation for Nobivac NXT HCPChFeLV marks the first instance of innovative self-amplifying RNA (saRNA) technology entering the commercialization phase (Approval/Marketed) in the global feline vaccine market, valued at $1.5 billion in 2025. From a researcher's perspective, the hybrid design combining live attenuated antigens with the saRNA platform has demonstrated safety through 15 controlled clinical trials, setting a standard for future multi-target vaccine designs. From an industry professional's perspective, Merck (MRK) has secured a technological advantage, enabling it to potentially reshape the competitive landscape in the pet vaccine market, traditionally dominated by Zoetis (ZTS) and Boehringer Ingelheim, and gain a market share of over 23% in the leading group. In the short term, growth in the European market is expected, and in the medium to long term, it is anticipated that cost competitiveness and maximized productivity will be achieved through reduced development time and the elimination of preservatives and adjuvants.